How Moderna execs are cashing in during the race to develop COVID-19 vaccine
Biotech firm Moderna Inc. could reap tens of billions of dollars in sales and stock appreciation if it wins the race for a COVID-19 vaccine. If it loses, the early-stage company’s value could crash. In the meantime, the firm’s chief executive is pocketing millions of ...
Health experts slam U.S. deal for large supply of coronavirus drug
Public health experts on Wednesday criticized the U.S. for securing a large supply of the only drug licensed so far to treat COVID-19. The U.S. government announced this week that it had an agreement with Gilead Sciences to make the bulk of their production of ...
How China's CanSino Biologics jumped to the front of the coronavirus vaccine race
The firm has boosted its scientific prowess by tying up with the Canadian government’s largest research organization, maintaining links despite geopolitical rows.
Eisai to start clinical trial of experimental drug for COVID-19
Japanese pharmaceutical firm Eisai Co. is set to start clinical trials in the United States of its experimental drug eritoran in the battle against coronavirus, with results potentially available by the year-end, the company said Wednesday. Eisai will test eritoran, initially developed to treat severe ...
Fujifilm ties up with Indian firm on potential COVID-19 drug Avigan
The drug has yet to be approved by the Japanese government for coronavirus treatment, with clinical testing delayed due to insufficient enrollment.
Trials set to begin in Osaka as countries race to produce COVID-19 vaccine
With more than 100 research projects underway to develop vaccines for the novel coronavirus, the United States, Europe and China have taken the lead.
Wanted: More COVID-19 patients in Japan ... for clinical trials
Japan has become a victim of its own success as slowing new infections have led to a shortage of patients to enroll in trials for treatments and vaccines.
Osaka's Rohto to begin stem cell clinical trial for COVID-19 in August
Rohto Pharmaceutical Co. said Tuesday it will begin a clinical trial in August using stem cells for a potential treatment for patients severely ill with COVID-19. The Osaka-based drugmaker said it will be the first time in Japan that domestic stem cells have been used ...
Gilead targets remdesivir supply for 2 million COVID-19 patients by year-end
The company also said it hoped to start trials in August of an easier-to-use inhaled version of the medicine, which is currently administered only intravenously.
Japan drugmaker to tie up with universities to develop new test method for coronavirus
Japanese pharmaceutical company Shionogi & Co. said Monday that it will collaborate with universities in the country to put into practical use a new testing method for the novel coronavirus.
Nobel laureate Honjo sues Ono Pharmaceutical over royalties from Opdivo
The Kyoto University professor is demanding about ¥22.6 billion, claiming the firm slashed his share of royalty income the cancer-fighting drug.
Osaka human trials of AnGes coronavirus vaccine to start June 30
Osaka Mayor Ichiro Matsui stressed the importance of developing a vaccine in Japan.
